For patients receiving salvage radiation therapy and 6 mo of androgen deprivation therapy for prostate cancer recurrence after radical prostatectomy, addition of abiraterone + apalutamide improved outcomes for patients with prostate-specific antigen >0.5 ng/ml.
For patients receiving salvage radiation therapy and 6 mo of androgen deprivation therapy for prostate cancer recurrence after radical prostatectomy, addition of abiraterone + apalutamide improved outcomes for patients with prostate-specific antigen >0.5 ng/ml.